Aggregated price index with volume information
Summary:
- The momentum of the sector is very strong.
- Gene Therapy stocks down 0.2% on average while median return down 0.4% in a day
- Gene Therapy stocks up 7.3% on average while median return up 7.7% in a week
- Gene Therapy stocks up 22.7% on average while median return up 17.5% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $QURE 86.9%, $SLDB 63.0%, $BLUE 34.1%, $RGNX 24.5%, $MGTX 20.2%
- 1M losers are : Losers for past month are $BMRN -0.8%, $CAPR -5.6%, $SRPT -8.1%
- 1W winners are : Winners for past week are $BLUE 16.2%, $MGTX 14.5%, $RGNX 13.9%, $EDIT 13.0%, $SLDB 13.0%
- 1W losers are : Losers for past week are $SRPT -0.9%, $CAPR -6.8%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 30.0%, for the past 3 months is 21.4%
In the past month for a 5 days rolling window, the highest corrrelation is 50.6%, the lowest correlation is 4.3%, the latest correlation is 39.2%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 82.0% between EDIT and NTLA
The lowest correlation is -29.6% between ADVM and SRPT
Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.
On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
The consensus price target hints at a 125.9% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, August 1, 2024, to discuss its financial results and corporate update for the quarter ending June 30, 2024. The live and replayed webcast of the call will be available through th
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2024, and recent operational highlights.
The sBLA for BRINEURA was supported by data from a Phase II trial.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental Biologics License Application (sBLA) for BRINEURA® (cerliponase alfa) to slow the loss of ambulation in children of all ages with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency. Previously, BRINEURA was indicated in symptomatic children 3 years of age and older with late infantile CLN2 d
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that it awarded inducement grants on July 22, 2024 to its Executive Vice President and Chief Financial Officer, Edward Dulac, under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of non-qualified stock options to purchase
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
CRISPR Therapeutics (CRSP) stock has been pushing downwards in recent weeks, taking it near a 52-week low. The stock’s fall likely reflects the broader selloff and rotation away from technology stocks. This dip could present a buying opportunity at a discounted price. I’m still bullish on CRISPR because of its market-leading portfolio of gene-editing therapies and first-to-market position in the treatment of sickle cell disease (SCD), though I do accept that there are challenges ahead. CRISPR Th